NCT05608291: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 3 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05608291 |
|---|---|
| Title | A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 16, 2023 |
| Completion date | May 16, 2028 |
| Required reporting date | May 16, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |